Pegargiminase
- Generic Name
- Pegargiminase
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1394129-74-8
- Unique Ingredient Identifier
- 0B7PYQ9YRT
- Background
Pegargiminase is an anticancer agent.
- Indication
Investigated for use/treatment in melanoma and hepatocellular carcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 98
- Registration Number
- NCT03449901
- Locations
- πΊπΈ
Columbia University Medical Center, New York, New York, United States
πΊπΈSarcoma Oncology Center, Santa Monica, California, United States
πΊπΈStanford Medicine, Palo Alto, California, United States
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 23
- Registration Number
- NCT02875093
- Locations
- π¨π³
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
π¨π³National Cheng Kung University Hospital, Tainan, Taiwan
π¨π³Chang Gung Memorial Hospital - Linkou, Taoyuan, Taiwan
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 21
- Registration Number
- NCT02101580
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 8
- Registration Number
- NCT02101593
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
πΊπΈSeattle Cancer Care Alliance, Seattle, Washington, United States
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 85
- Registration Number
- NCT02029690
- Locations
- π¬π§
Cambridge Hospital, Cambridge, United Kingdom
π¬π§Guys Hospital, London, United Kingdom
π¬π§Centre for Experimental Cancer Medicine (CECM), London, England, United Kingdom
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 30
- Registration Number
- NCT02006030
- Locations
- π¨π³
TP-VGH, Taipei City, Taiwan
π¨π³CGMH-LK, Taoyuan, Taiwan
π¨π³National Taiwan University Hospital, Taipei, Taiwan
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 15
- Registration Number
- NCT01948843
- Locations
- πΊπΈ
M.D. Anderson Cancer Center, Houston, Texas, United States
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 43
- Registration Number
- NCT01910012
- Locations
- π¨π³
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
π¨π³CMUH, Taichung, Taiwan
π¨π³NCKUH, Tainan City, Taiwan
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 18
- Registration Number
- NCT01910025
- Locations
- π¨π³
Chang Gung Medical Foundation-Kaohsiung, Kaohsiung City, Taiwan
π¨π³National Cheng Kung University Hospital(NCKUH), Tainan City, Taiwan
π¨π³CMUH, Taichung, Taiwan
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 8
- Registration Number
- NCT01665183
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
π¨π³NCKUH, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.